SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Persistent symptoms following SARS-CoV-2 infection amongst children and young people: A meta-analysis of controlled and uncontrolled studies.

Behnood, SA; Shafran, R; Bennett, SD; Zhang, AXD; O'Mahoney, LL; Stephenson, TJ; Ladhani, SN; De Stavola, BL; Viner, RM; Swann, OV (2022) Persistent symptoms following SARS-CoV-2 infection amongst children and young people: A meta-analysis of controlled and uncontrolled studies. J Infect, 84 (2). pp. 158-170. ISSN 1532-2742 https://doi.org/10.1016/j.jinf.2021.11.011
SGUL Authors: Ladhani, Shamez Nizarali

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (2MB) | Preview
[img] Microsoft Word (.docx) (Supplementary materials 1) Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (115kB)
[img] Microsoft Word (.docx) (Supplementary materials 2) Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (22kB)

Abstract

BACKGROUND: Data on the long-term impact of SARS-CoV-2 infection in children and young people (CYP) are conflicting. We assessed evidence on long-term post-COVID symptoms in CYP examining prevalence, risk factors, type and duration. METHODS: Systematic search of published and unpublished literature using 13 online databases between 01/12/2019 and 31/07/2021. Eligible studies reported CYP ≤19 years with confirmed or probable SARS-CoV-2 with any symptoms persisting beyond acute illness. Random effects meta-analyses estimated pooled risk difference in symptom prevalence (controlled studies only) and pooled prevalence (uncontrolled studies also included). Meta-regression examined study characteristics hypothesised to be associated with symptom prevalence. Prospectively registered: CRD42021233153. FINDINGS: Twenty two of 3357 unique studies were eligible, including 23,141 CYP. Median duration of follow-up was 125 days (IQR 99-231). Pooled risk difference in post-COVID cases compared to controls (5 studies) were significantly higher for cognitive difficulties (3% (95% CI 1, 4)), headache (5% (1, 8)), loss of smell (8%, (2, 15)), sore throat (2% (1, 2)) and sore eyes (2% (1, 3)) but not abdominal pain, cough, fatigue, myalgia, insomnia, diarrhoea, fever, dizziness or dyspnoea. Pooled prevalence of symptoms in post-COVID participants in 17 studies ranged from 15% (diarrhoea) to 47% (fatigue). Age was associated with higher prevalence of all symptoms except cough. Higher study quality was associated with lower prevalence of all symptoms, except loss of smell and cognitive symptoms. INTERPRETATION: The frequency of the majority of reported persistent symptoms was similar in SARS-CoV-2 positive cases and controls. This systematic review and meta-analysis highlights the critical importance of a control group in studies on CYP post SARS-CoV-2 infection.

Item Type: Article
Additional Information: /© 2021 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Keywords: COVID-19, Children and young people, Long COVID, Paediatric, Post-COVID syndrome, SARS-CoV-2, Adolescent, COVID-19, Child, Fatigue, Fever, Headache, Humans, SARS-CoV-2, Humans, Headache, Fever, Fatigue, Adolescent, Child, COVID-19, SARS-CoV-2, COVID-19, Long COVID, Post-COVID syndrome, Children and young people, Paediatric, SARS-CoV-2, 1103 Clinical Sciences, Microbiology
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: J Infect
ISSN: 1532-2742
Language: eng
Dates:
DateEvent
14 February 2022Published
20 November 2021Published Online
16 November 2021Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
PubMed ID: 34813820
Web of Science ID: WOS:000759978600016
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/114694
Publisher's version: https://doi.org/10.1016/j.jinf.2021.11.011

Actions (login required)

Edit Item Edit Item